This article is more than 5 years old. Information may no longer be current.
Seattle Genetics, Genentech to collaborate on trial for metastatic triple-negative breast cancer
Click Here to Manage Email Alerts
Seattle Genetics and Genentech entered a clinical collaboration to evaluate SGN-LIV1A in combination with atezolizumab for the treatment of metastatic triple-negative breast cancer.
“A key challenge in triple-negative breast cancer is the lack of available novel targeted treatments,” Robert Lechleider, MD, senior vice president of clinical development at Seattle Genetics, said in a company-issued release. “People with this disease generally have poor prognoses. Moreover, current therapies are not curative and only delay disease progression.”
Phase 1 data show SGN-LIV1A (Seattle Genetics) — which consists of a LIV-1-targeted monoclonal antibody linked to the potent cell-killing agent monomethyl auristatin E — has activity as monotherapy in heavily pretreated, metastatic triple-negative breast cancer.
A randomized-controlled phase 1b/phase 2 study — anticipated to enroll up to 45 patients in the treatment arm — will investigate the combination of SGN-LIV1A with atezolizumab (Tecentriq, Genentech), and anti-PD-L1 agent, as a second-line therapy in patients who were not previously treated with immunotherapy.
“Now, under this new collaboration, we will evaluate the potential to expand therapeutic benefit to these patients through combination therapy with atezolizumab,” Lechleider said.
The combination will be tested in the MORPHEUS platform (Roche), a phase 1b/phase 2 adaptive platform to develop combinations of cancer immunotherapies rapidly and efficiently.
Under terms of agreement, Genentech will manage the study operations of the trial.